Author

John C. Woolcott

PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME
PATIENT-REPORTED OUTCOME IMPROVEMENT WITH TOFACITINIB IN THE ULCERATIVE COLITIS OCTAVE CLINICAL PROGRAMME

John C. Woolcott  et al.

PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME
PRESENCE OF RISK FACTORS ASSOCIATED WITH COLECTOMY AMONG PATIENTS WITH COLECTOMY IN THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAMME

John C. Woolcott  et al.

CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE
CHARACTERISTICS AND REAL WORLD TREATMENT HISTORY OF PATIENTS TREATED WITH TOFACITINIB FOR ULCERATIVE COLITIS IN EUROPE

John C. Woolcott  et al.

SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS
SYMPTOMATIC IMPROVEMENT OBSERVED WITHIN 2 DAYS OF ETRASIMOD INDUCTION THERAPY: RESULTS FROM ELEVATE UC 52 AND ELEVATE UC 12 STUDIES IN PATIENTS WITH ULCERATIVE COLITIS

John C. Woolcott  et al.

ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME
ANALYSIS OF INFECTIONS OF INTEREST IN PATIENTS TREATED WITH TOFACITINIB IN THE ULCERATIVE COLITIS CLINICAL PROGRAMME

John C. Woolcott  et al.

HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
HEPATIC IMPACT OF ETRASIMOD FOR TREATMENT OF MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTEGRATED SAFETY SUMMARY FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

John C. Woolcott  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

John C. Woolcott  et al.

CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL
CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL

John C. Woolcott  et al.

HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB
HISTOLOGICAL OUTCOMES AND THE IMMUNE LANDSCAPE IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB

John C. Woolcott  et al.

IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME
IMPACT OF ETRASIMOD ON BLOOD PRESSURE AND HYPERTENSION: DATA FROM THE ETRASIMOD ULCERATIVE COLITIS CLINICAL PROGRAMME

John C. Woolcott  et al.

RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH
RESPONSE TO TOFACITINIB IN ULCERATIVE COLITIS PREDICTED BY A MACHINE-LEARNING ALGORITHM; A MULTI-OMICS APPROACH

John C. Woolcott  et al.

Item 1 - 11 / 11
1